#### 1

#### 1 LncRNA antigens- a novel resource to improve immunotherapy efficacy

## 2 predictions in Melanoma

## 3 Authors

- 4 Sumaira Malik, School of Mathematical and Statistical Sciences, University of
- 5 Galway, Ireland, s.malik3@nuigalway.ie
- 6 Aaron Golden, School of Natural Sciences, University of Galway, Ireland,
- 7 aaron.golden@universityofgalway.ie
- 8 Corresponding author: Sumaira Malik, s.malik3@nuigalway.ie

## 9 Key Words

- 10 Immunotherapy efficacy, Biomarker, LncRNA sORFs, Prognostic value, Antigen
- 11 load, Melanoma, Tumor immune response

## 12 Abstract

## 13 Background:

- 14 ICI (immune checkpoint inhibitor) therapy is one of the most promising treatments for
- 15 melanoma. ICI response however varies among patients, emphasizing the importance
- 16 of identifying genomic biomarkers to predict likely therapeutic efficacy in advance of
- 17 treatment. We hypothesised that a lncRNA based immunogencity (lnc-IM) score
- 18 could be used to predict individual response to ICI treatment, and that this could
- 19 complement the existing criterion for ICI selection based on tumor mutation burden
- 20 (TMB).

## 21 Methodology:

- 22 The TCGA-SKCM (n=101) and the ICI treated UCLA (n=25), MSKCC (n=16) and
- 23 DFCI (n=40) melanoma cohorts were used in this study, involving both clinical and
- 24 transcriptomic data. Each patient was assigned an lnc-IM score based on the number
- 25 of lncRNA sORF derived peptides predicted to be presented by their tumor's MHC-I
- 26 genotype. For the ICI treated cohorts, a combined antigen score was defined as a sum
- of neo-antigen load (derived from TMB) and lnc-IM score. A logistic regression-
- 28 based classifier was used to predict ICI responses based on these combined antigen
- 29 scores.

## 30 Results:

- 31 Survival analysis showed improved overall survival among patients with low lnc-IM
- 32 scores (HR= 0.39, p=0.009) in the TCGA-SKCM cohort. We also observed a negative
- 33 association between tumor immune cell concentration and lnc-IM scores, with low
- 34 lnc-IM groups showing higher anti-tumor immune cell concentrations . Using the ICI
- 35 treated cohorts, we demonstrated that a classifier based on combined antigen scoring
- 36 improved the prediction of immunotherapy outcomes as compared to using TMB
- alone, yielding an area under the curve (AUC) of 0.71 with an accuracy of 0.54 and
- 38 recall of 1. We also demonstrated a reduced rate of false negatives (14%) by using a
- 39 combined antigen score as compared to the use of TMB alone (33%) in ICI treated
- 40 cohorts.
- 41 **Conclusion:** Our findings suggest that the use of combined antigen scores (using lnc-
- 42 IM scores along with TMB derived neoantigen load) have potential in improving
- 43 immunotherapy efficacy predictions. Prospective validation in larger cohort sizes is
- 44 warranted.

3

## 45 KEY MESSAGES:

## 46 What is already known on this topic

- 47 Previous studies have established actionable associations between TMB neoantigen
- 48 load and immunotherapy responses.

#### 49 What this study adds

- 50 This study introduces lnc-IM scores as a novel metric that predicts patients antigen
- 51 load based on translatable lncRNAs expression. These lnc-IM scores when combined
- 52 with TMB associated neoantigen load indicate an improvement in immunotherapy
- 53 efficacy predictions.

#### 54 How this study might affect research, practice or policy

Future research is needed to further validate lnc-IM scores as a predictive biomarker for immunotherapy response in various cancer types. The use of lnc-IM scores can empower clinicians to make more informed decisions about administering immunotherapy treatments, improving patient outcomes.

4

#### 59 INTRODUCTION

60 Self versus non-self discrimination by T cells is a hallmark of cancer evasion by the 61 immune response [1]. T cells eliminate cancer cells by recognizing tumor-specific 62 antigens presented on the tumor cell's surface by MHC-I molecules [2]. Immune and 63 tumor cells possess "checkpoint proteins" such as PD-1, CTLA4 and PDL1 that keep 64 such immune responses in check with the binding of such checkpoint proteins 65 restricting T cells from killing tumor cells. Immune checkpoint inhibitor therapy (ICI) 66 is a promising immunotherapy that restores the T cells' capacity to attack and 67 eliminate tumor cells by blocking such checkpoint proteins [3].

68 The use of ICI therapy has been a significant achievement in the last decade for 69 cancer treatment and has demonstrated clear improvements in the survival rate of 70 cancer patients. Its use to date has been approved for multiple cancer types, including 71 melanoma - one of the first cancers to be treated with this therapy [4]. Despite some 72 remarkable successes, response to ICI therapy varies widely among individual 73 patients, emphasizing the importance of identifying genomic biomarkers to try and 74 predict an individual's likely response in advance of treatment. Tumor mutation 75 burden (TMB), programmed cell death ligand 1 (PDL1), and mismatch repair defect 76 (dMMR)/microsatellites Instability (MSI) are some of the currently FDA-approved 77 predictive biomarkers of ICI efficacy, of which TMB is the most widely used [5,6]. 78 High TMB has been shown to predict improved therapeutic efficacy to ICI therapy in 79 various cancer types [7]. High TMB is associated with a high neoantigen burden [7]; 80 hence, ICI therapy for patients whose cancers have a high TMB would be expected to 81 elicit significant T cell responses against those antigens, resulting in enhanced tumor 82 cell attrition. Although many trials have demonstrated the usability of TMB in clinical

5

practices, a recent study has questioned the concept of the universal usage of TMB as
a predictor of ICI efficacy [8], arguing that TMB prediction power is only accurate to
a subset of patients, and using TMB as a sole predictor of ICI response might deprive
potential patients who might otherwise respond to ICI therapy .

87 TMB-associated antigens (neoantigens) are derived from non-synonymous missense 88 mutations and originate from the coding region of the genome that encodes proteins 89 [9]. However, TMB is not the only source of antigens. The Encyclopedia of DNA 90 Elements (ENCODE) revealed that the human genome contains almost 80% of non-91 coding RNAs in contrast to the 1.5% that encodes for proteins [10]. Among non-92 coding RNAs, those longer than 200 nucleotides in length - collectively known as 93 long non-coding RNAs or lncRNAs - are of great interest on account of their evident 94 wide functional diversity [11]. LncRNAs have been studied for their ability to control 95 regulatory and cellular processes. LncRNAs regulate gene expression both as miRNA 96 sponges and mRNA sponges [12]. LncRNAs act as transcription regulators by 97 modifying the chromatin complexes and can activate or repress gene expression. 98 Moreover, they also control the binding of transcription regulatory factors leading to 99 the activation of nearby genes [13].

100 LncRNAs have also been shown to be implicated in the creation of MHC-I associated 101 peptides with additional work demonstrating that a considerable number of tumor-102 specific antigens originate from non-coding regions of the genome [14]. LncRNAs' 103 contribution to the cancer immunopeptidome is a topic of active research with a 104 particular focus being an assessment of whether such lncRNA-associated antigens are 105 associated with elevated cytotoxic T lymphocyte (CTL) responses. High CTL 106 responses have been associated with better survival and treatment outcomes [15]. 107 Many lncRNAs possess intact short open reading frames (sORF) that can result in the

6

108 translation of short peptides in the dysregulated cancer transcriptome. Whilst short 109 peptides have been detected in mass-spectrometry based proteomic studies [16], direct 110 association of lncRNA sORFs with tumor immune microenvironment (TIM) has yet 111 to be fully characterised. 112 In this study we explore how the expression of lncRNA sORFs is associated with a 113 patient's likely response to ICI therapy. Specifically, we derive a novel metric, the lnc-114 IM score, that estimates the level of sORF derived peptide presentation based on a 115 tumour's specific MHC-I genotype. In the first part of our study, we establish the 116 association of lnc-IM scores with the tumor immune microenvironment – determined 117 from known cellular biomarkers - and survival predictions in a melanoma cohort 118 (TCGA-SKCM) without any ICI treatment. In the second part, we utilize three ICI-119 treated melanoma cohorts to examine how these lnc-IM scores can be used to improve 120 ICI efficacy predictions by their integration with each patient's TMB-associated 121 antigen count.

#### 122 METHODS

#### 123 Data acquisition

124 For this study, three different publicly available melanoma cohorts were utilized. 125 Clinical information and transcriptomic profiles (RNA-seq) of the TCGA-SKCM 126 cohort were downloaded from The Cancer Genome Atlas (TCGA, https://portal. 127 gdc.cancer.gov). HLA typing of the TCGA-SKCM cohort was acquired from a 128 previous study [17]. A total of 101 patients were included in our analysis based on 129 the availability of MHC-I genotype and transcriptomic data and having basic clinical 130 information of age, gender, and overall survival. For ICI efficacy predictions, three 131 ICI-treated cohorts involving metastatic melanoma (UCLA) [18], melanoma

7

132 (MSKCC) [19] and metastatic melanoma (DFCI) [20] patient groups were utilized. 133 Clinical information, including overall survival, treatment response, TMB, neoantigen load. 134 and transcriptomic data, was retrieved from cBioPortal 135 (https://www.cbioportal.org/) [21]. Based on the criteria mentioned above, a total of 136 16 patients from the MSKCC cohort, 25 from the UCLA cohort and 40 from DFCI 137 cohort were selected for subsequent analysis. Tumor immune microenvironment 138 (TIM) analysis for the TCGA-SKCM cohort was performed using the xCell algorithm 139 [22], which estimates the the abundance of each immune cell type using expression 140 profiles of specific gene signatures for each cell type.

## 141 Defining Lnc-IM scores

142 A lncRNA-immunogenicity score (lnc-IM) for a patient was defined as the total 143 number of presentable lncRNA associated sORFs for that patient's tumor. In the first 144 step, all lncRNAs associated with short open reading frames (sORFs) were retrieved 145 from sORFs.org [23]. We selected our desired dataset from sORFs.org based on filters 146 (species: humans and biotype = lncRNA). This initial search resulted in 425 lncRNAs 147 and will be referred to as translatable lncRNAs in this work. These lncRNAs are 148 associated with  $\sim 3000$  sORFs, as experimentally proven by different Riboseq 149 experiments [23]. Among these translatable lncRNAs, only overexpressed lncRNAs 150 were considered for subsequent analysis. The raw RNA-seq expression of translatable 151 lncRNAs was acquired from GDC (TCGA, https://portal. gdc.cancer.gov) and 152 cBioPortal (https://www.cbioportal.org/). Raw counts were converted to counts per 153 million (cpm) and log normalized using the edgeR [24] package in R. A translatable 154 lncRNA was considered for immunogenicity scoring if it passed the criteria of (log 155 cpm > 6) (Supplemental Figure 1). For each translatable lncRNA, all of its sORFs 156 were considered for lnc-IM scoring. The Patient Harmonic-mean Best Rank (PHBR)

8

157 score [17] was then assigned to each sORF, which is an estimate of its derived 158 peptide's MHC-I presentation likelihood. The PHBR score represents the harmonic 159 mean of best-ranked peptides (across a given patient's HLA alleles). A sORF with 160 PHBR < 0.5 was used to define a "presentable sORF". The resulting lnc-IM score 161 (Supplemental Figure 2) represents the total number of presentable sORFs in a given 162 patient's tumor.

## 163 Combined antigen score

For the ICI-treated cohorts, a combined antigen score was derived as a sum of each patient's TMB associated neoantigen burden (using the methodology previously articulated by [18, 19, 20]) and lnc-IM score (as previously defined by us). Any overlapping loci between sORFs and neoantigen loci were identified and removed to avoid the repetition of potential antigens.

#### 169 Statistical Analysis

170 All analyses were implemented using R (v.3.6.3). Patients were divided into high, 171 lnc-IM and combined antigen groups using the *surv\_cutpoint* low and 172 surv categorize functions from the survminer package in R [25]. Cutpoints for 173 dividing data into high/low immunogenic groups based on lnc-IM scores and 174 combined antigen scores were chosen for each cohort separately using maximally 175 ranked statistics (Supplemental Figure 2 and Supplemental Table 1). To determine the 176 prognostic value of lnc-IM scores, Kaplan Meier survival plots were generated using 177 the survival R package [26]. Spearman's correlation and Wilcoxon test were 178 conducted using the ggpubr [27] R package to determine the association of lnc-IM 179 scores with tumor immune cells. A significance level of 0.05 was used as the cutoff, 180 with p < 0.05 considered as the statistically significant difference for all tests.

9

181 Three ICI-treated cohorts were utilized to determine the predictive value of combined 182 antigen score. Patients were stratified into the high and low combined immunogenic 183 groups as described above, and a logistic regression-based classifier was utilized to 184 predict immunotherapy responses using stats [28] package in R. Patients were 185 randomly assigned to training 70% and test 30% groups. For performance assessment, 186 the evaluation metrics area under the curve (AUC), accuracy and recall were 187 calculated using R packages *caret* and *caTools* [29, 30]. We compared the prediction 188 power of combined antigen scores with TMB using overall response rates, true 189 positive rates and false negative rates.

#### 190 RESULTS

## 191 Lnc-IM scores are associated with anti-tumor immune responses

192 The tumor immune microenvironment (TIM) is critical in understanding disease 193 progression and predicting treatment responses. Tumor infiltrating lymphocytes 194 (TILs) comprises of a complex set of cells in the TIM that play important roles in both 195 tumor progression and suppression [31]. Based on these roles, these cells can be 196 divided into anti-tumor and pro-tumor immune cell groups. Tumor-associated 197 antigens are known to enhance TILs associated immune responses against tumor cells 198 [31]. To this end, we investigated the association of lncRNA antigen load using lnc-199 IM scores with abundance of aDC, B cells, macrophages (M1 and M2), CD8-T cells, 200 CD4 memory T-cells, T regulatory cells, Th1 and Th2 cells. Six of these cell types 201 were characterized as anti-tumor immune cells based on their known involvement in 202 tumor surveillance mechanisms, and three were characterized as pro-tumor immune 203 cells. Three of six anti-tumor immune cells showed significant differences between 204 the high and low lnc-IM groups. None of the pro-tumor immune cells showed a

10

significant association between the two groups (Figure 1). Taken together these data
show a significant association between lnc-IM scores and elevated anti-tumor immune
responses.

## 208 Lnc-IM scores are associated with survival predictions

209 High tumor infiltrating lymphocytes (TILs) levels have been associated with the 210 immune system's capacity to eliminate tumor cells [32]. Hence, patients with high 211 TILs show improved survival compared to those with low TILs. Knowing the value of 212 TILs in survival prediction [33] and the association of lnc-IM scores with TILs 213 (Figure 1), we next questioned if lnc-IM scores could be used to predict survival in 214 the TCGA-SKCM cohort. The results showed that patients in the low lnc-IM category 215 (n = 59) showed better overall survival (HR = 0.39, p = 0.009) than in the high lnc-IM 216 category (n = 42) (Figure 2). The overall median survival remained at 1070 days 217 among the low lnc-IM group, while it reduced to 721 days in the high-IM group. The 218 baseline characteristics of all patients are shown in Table 1. In order to check the 219 association of any confounding variables with survival predictions, a multivariate 220 analysis was performed using age, gender, and cancer stage and lnc-IM scores (Figure 221 3). None except lnc-IM scores, were significantly associated with survival predictions.

	TCGA-SKCM	UCLA	MSKCC	DFCI
Gender				
Female	42	11	25	14
Male	59	27	39	26
Age				
≤50	15	7	14	12
>50	86	31	47	28
Treatment				
Iplimumab	-	-	60	40
Pembrolizumab	-	36	-	-
Nivolumab	-	2	-	-
Tremelimumab	-	-	4	-
Responders	-	21	14	5
Cancer stage				
I/II	72	-	-	-
III/IV	29	-	-	-

222

Table 1: Baseline features of cohorts used in this study. For ICI treated cohorts MSKCC, UCLA only subset of patients was selected for downstream analysis (as explained in Methods: Data acquisition).

## 223 ICI efficacy predictions based on combined antigen score

224 Based on the association of lnc-IM scores with both TILs and survival, we evaluated 225 how such scoring can help improve immunotherapy outcomes prediction. We 226 hypothesized that using a combined antigen score that includes both lncRNA-227 associated antigen scores and TMB-associated neoantigen scores can give a fuller 228 picture of the tumor's immunopeptidome and so enhance the prediction of ICI efficacy. Such scoring could also help predict ICI outcomes for patients' whose 229 230 tumors are not hypermutated (i.e have a high TMB) and so would not be typically 231 considered for such treatment. Using both lnc-IM scores and TMB-derived neoantigen

12

232 load, a combined antigen score was assigned to each patient in the ICI-treated cohorts.

- 233 A logistic regression-based classifier was then adopted to build a prediction model for
- 234 immunotherapy outcomes in a combined cohort.
- 235 We evaluated the model's performance; our results showed an overall AUC of 0.71 in
- 236 discriminating between responders and non-responders (accuracy = 0.54 and recall =
- 237 1). We compared this model with TMB based model (FDA approved cutoff > 10
- 238 mutations/megabase (mut/Mb) was used for dividing patients into high and low TMB
- 239 groups). The results showed an improved performance of combined antigen scoring as
- 240 compared to TMB based model (Table 2).

#### 241

<b>Evaluation Metric</b>	Combined antigen score	ТМВ
AUC	0.71	0.53
Recall	1	0.4
Accuracy	0.54	0.5

Table 2: Evaluation metrics for combined antigen scoring and TMB based models.

## 242 Combined antigen score performs better than TMB alone as biomarker

243 To further assess whether predictions based on combined antigen score performed 244 better than using TMB alone, we compared overall response rates (ORR) between the 245 high TMB group and high combined antigen score in all three ICI treated cohorts. 246 The ORR improved in high combined antigen score as compared to high TMB among 247 UCLA and MSKCC cohorts while remaining the same for DFCI cohort (Figure 4). 248 Among these ICI treated cohorts, 21 out of 81 patients responded to therapy. Using a 249 high combined antigen score (cutoff criterion showed in Supplemental Material Table 250 1) as a classifier, 18 out of these 21 were correctly identified as responders. In 251 contrast, using TMB alone using the same classifier formalism correctly categorizes 252 only 14 responders. An additional advantage of using a combined strategy is the goal 253 of minimizing the false negative rate to ensure a robust classification that would not 254 deprive potential responders of therapy. In Figure 5 we show that the false negative 255 rate decreased from 33% to 14% using combined antigen score than TMB alone. 256 These results demonstrate strong evidence that using combined antigen score can help 257 improve prediction efficacy for patients who might have a low mutation burden but 258 still can benefit from treatment.

14

#### 259 **DISCUSSION**

260 In this bioinformatics-based study, we introduced a novel metric "lnc-IM scores" 261 incorporating translatable lncRNA expression and patient MHC-I genotype and 262 combined them with TMB-associated neoantigen load to create a predictive 263 biomarker "combined antigen score" for ICI outcomes. TCGA SKCM data revealed 264 the prognostic value and association of lnc-IM scores with the tumor immune 265 microenvironment. Additionally, the value of combined antigen score as a predictive 266 biomarker was investigated using ICI-treated cohorts (UCLA n=27, MSKCC n=21, DFCI n=40), previously used to investigate TMB-associated ICI response alone. 267

268 Among the TCGA SKCM cohort, lncRNA immunogenicity scores were significantly 269 associated with anti-tumor immune responses. TILs associated with anti-tumor 270 immune responses showed significant differences between high and low lnc-IM 271 groups. Interestingly, all of these cells were upregulated in the low lnc-IM group. 272 These findings appear to be in accordance with recent pan-cancer studies where high 273 TMB/high antigen groups were associated with depressed immune cell infiltration in 274 different cancer types [34]. One of the possible explanations for such trends could be 275 that the quality/immunogenicity of antigen being presented is responsible for a better 276 immune response than the quantity of antigens [35]. A study previously showed that 277 certain antigens belonging to ERVs were associated with high antigen specific CD8-278 Tcell infiltrate as compared to other antigens that were associated with rare antigen 279 specific CD8-T cells population [15]. Other critical factors are the tumor immune 280 evasion mechanisms that are prevalent in high immunogenic groups. Cancers tend to 281 evade immune responses by downregulating MHC molecules and TAP3 proteins, so 282 these antigens are not efficiently presented on cancer cell surfaces [36]. Hence, we see 283 a decrease in immune cell infiltration in such cancers.

15

TILs have been linked to prognostic outcomes in various types of cancer. In general, elevated levels of TILs within a tumor correspond to a more aggressive anti-tumor immune microenvironment and are associated with better survival outcomes compared to tumors with low TILs, as previously reported [37]. Our study (as illustrated in Figure 1 and Figure 2) supports this finding by demonstrating that patients with low lnc-IM tumors generally had greater anti-tumor TILs and better survival outcomes than those with high lnc-IM tumors.

291 We hypothesized that using lnc-IM scores along with conventional TMB might help 292 improve efficacy predictions. We determined that the overall response rates improved 293 using high combined antigen score as compared to using TMB alone. An essential 294 factor is to ensure that the combined antigen score based classifier helps decrease the 295 false negative rate to avoid depriving actual responders of ICI therapy. We have 296 demonstrated that using the high combined antigen score compared to high TMB 297 alone cannot only improve the true positive rate but also help decrease the false 298 negative rate (Figure 5). In these cohorts, using high TMB alone as a biomarker could 299 deprive 33% of potential responders of potentially efficacious ICI therapy. However, 300 in our small study we demonstrated by using high combined antigen scores reduced 301 this percentage to 14%. These findings have specifically highlighted the predictive 302 power of combined antigen approach scores for responders with low TMB but high 303 lnc-IM scores.

The key limitations of this study are the small sample size, the retrospective nature of cohorts used, and the variability of the type of ICI treatment administered. ICI treatments vary based on the type of checkpoint protein targeted (PD-1 or CTLA4). Both treatments show potential for melanoma treatment with 58% ORR for anti-PD-1 and 38% ORR for anti-CTLA4 therapy in melanoma [38]. Using both primary

16

309 (TCGA-SKCM) and metastatic cohorts (ICI treated) in our study may have 310 advantages and limitations. On the one hand, the inclusion of both sample types 311 increased the sample size of the study, enhancing our ability to identify more 312 inclusive and robust prognostic and predictive biomarkers. On the other hand, using 313 both cohorts may present challenges due to the potential differences in molecular 314 profiles between primary and metastatic tumors. We note however, a recent study 315 showing no significant difference between primary and metastatic melanoma TMB 316 [39]. We have demonstrated an association of the lnc-IM score with the TIM, 317 survival, and ICI outcomes prediction in three different cohorts providing confidence 318 as regards the added value of the lnc-IM scores as a biomarker. It is also worth noting 319 that the predictive power of combined antigen scoring was evaluated specifically in 320 metastatic tumors. Further validation in a larger cohort size is required to determine 321 the optimal cutoff for the lnc-IM and combined antigen scores.

Future research would ideally focus on determining the value of lnc-IM scores in other cancer types that are not hypermutated yet still respond to ICI therapy, involving larger cohort sizes.

325 Acknowledgements: This project was supported by a Hardiman Research
326 Scholarship, University of Galway, Ireland

327 **Competing interest declaration:** None declared

**Ethics approval:** All the data used in this study were derived from existing publicly available databases and previously published studies. All the data were preanonymized. Thus, ethical approval was not required.

331 **Data availability statement**: Data can be provided on request.

17

## 332 List of Abbreviations

- 333 Immune checkpoint inhibitor therapy (ICI)
- 334 LncRNA based immunogencity score (lnc-IM score)
- 335 Tumor mutation burden (TMB)
- 336 Area under the curve (AUC)
- 337 Programmed cell death ligand 1 (PDL1)
- 338 Mismatch repair defect (dMMR)
- 339 Microsatellites Instability (MSI)
- 340 Encyclopedia of DNA Elements (ENCODE)
- 341 Cytotoxic T lymphocyte (CTL)
- 342 Short open reading frames (sORFs)
- 343 Tumor immune microenvironment (TIM)
- 344 The Cancer Genome Atlas (TCGA)
- 345 Counts per million (cpm)
- 346 Patient Harmonic-mean Best Rank (PHBR)
- 347 Tumor infiltrating lymphocytes (TILs)
- 348 Overall response rates (ORR)

18

#### 349 Hazard ratio (HR)

#### 350 **REFERENCES**

351

- Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell.
   2011;144(5):646–74.doi:10.1016/j.cell.2011.02.013
- Kanaseki T, Torigoe T. Proteogenomics: Advances in cancer antigen research. Immunological Medicine. 2019;42(2):65–70. doi:10.1080/25785826.2019.1640500
- 356
   3. He X, Xu C. Immune Checkpoint Signaling and cancer immunotherapy. Cell
   357 Research. 2020;30(8):660-9.doi:10.1038/s41422-020-0343-4
- Chen Q, Li T, Yue W. Drug response to PD-1/PD-L1 blockade: Based on biomarkers.
   OncoTargets and Therapy. 2018;11:4673–83.doi:10.2147/OTT.S168313
- 360 5. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint
  361 inhibitor immunotherapy. Nature Reviews Cancer. 2019;19(3):133–
  362 50.doi:10.1038/s41568-019-0116-x
- 363
  6. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy
  364 of PD-1/PD-L1 inhibitors. Molecular Cancer. 2018;17(1):129.doi:10.1186/s12943365 018-0864-3
- Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, et al.
  Tumor mutational burden and efficacy of immune checkpoint inhibitors: A systematic review and meta-analysis. Cancers. 2019;11(11):1798.doi:10.3390/cancers11111798
- 369 8. Gurjao C, Tsukrov D, Imakaev M, Luquette LJ, Mirny LA. Limited evidence of tumour mutational burden as a biomarker of response to immunotherapy. BioRxiv. 2020; 26(02):65.doi: <u>https://doi.org/10.1101/2020.09.03.260265</u>
- 372 9. Castle JC, Uduman M, Pabla S, Stein RB, Buell JS. Mutation-derived Neoantigens
  373 for cancer immunotherapy. Frontiers in Immunology.
  374 2019;10:1856.doi:10.3389/fimmu.2019.01856
- 10. International Human Genome Sequencing Consortium. Initial sequencing and
  analysis of the human genome. Nature. 2001;409: 860–
  921.doi:<u>https://doi.org/10.1038/35057062</u>
- 11. Zhang F, Zhang L, Zhang C. Long noncoding RNAS and tumorigenesis: Genetic Associations, molecular mechanisms, and therapeutic strategies. Tumor Biology. 2016;37(1):163–75.doi:10.1007/s13277-015-4445-4
- 381
  12. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A cerna hypothesis: The Rosetta
  382
  383 Stone of a hidden RNA language? Cell. 2011;146(3):353–
  383 8.doi:10.1016/j.cell.2011.07.014
- 13. Lee JT. Epigenetic regulation by long noncoding RNAS. Science.
  2012;338(6113):1435–9.doi:10.1126/science.1231776
- 14. Boon T, Van Pel A. T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis.
  189 Immunogenetics. 1989;29(2):75–9. doi:10.1007/BF00395854

19

390 391 392	15.	Laumont CM, Vincent K, Hesnard L, Audemard É, Bonneil É, Laverdure J-P, et al. Noncoding regions are the main source of targetable tumor-specific antigens. Science Translational Medicine. 2018;10(470):eaau5516.doi:10.1126/scitranslmed.aau5516
393 394 395	16.	Lv D, Chang Z, Cai Y, Li J, Wang L, Jiang Q, et al. TransLnc: A comprehensive resource for translatable lncrnas extends immunopeptidome. Nucleic Acids Research. 2021;50(D1):D413–D420.doi:10.1093/nar/gkab847.
396 397 398	17.	Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, et al. MHC-I genotype restricts the oncogenic mutational landscape. Cell. 2017;171(6):1272–83.doi:10.1016/j.cell.2017.09.050
399 400 401	18.	Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.doi:10.1016/j.cell.2016.02.065
402		
403 404 405	19.	Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New England Journal of Medicine. 2014;371(23):2189–99.doi:10.1056/NEJMoa1406498
406 407 408 409	20.	Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207-1.doi:10.1126/science.aad0095
410 411 412	21.	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative Analysis of Complex Cancer Genomics and clinical profiles using the cBioPortal. Science Signaling. 2013;6(269):pl1.doi:10.1126/scisignal.2004088
413 414	22.	Aran D, Hu Z, Butte AJ. xCell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biology. 2017;18(1):220.doi:10.1186/s13059-017-1349-1
415 416 417	23.	Olexiouk V, Crappé J, Verbruggen S, Verhegen K, Martens L, Menschaert G. sORFs.org: A repository of small orfs identified by ribosome profiling. Nucleic Acids Research. 2016;44(D1): D324–9.doi:10.1093/nar/gkv1175
418 419 420	24.	Robinson MD, McCarthy DJ, Smyth GK. edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40.doi:10.1093/bioinformatics/btp616
421 422 423 424	25.	Kassambara A, Kosinski M, Biecek P, Fabian S. Drawing survival curves using 'ggplot2' [R package survminer version 0.4.9]. The Comprehensive R Archive Network. Comprehensive R Archive Network (CRAN); 2021. Available from: https://cran.r-project.org/web/packages/survminer/
425 426 427	26.	Therneau TM. Survival analysis [R package survival version 3.5-3]. The Comprehensive R Archive Network. Comprehensive R Archive Network (CRAN); 2023. Available from: <u>https://cran.r-project.org/web/packages/survival/index.html</u>
428 429 430 431	27.	Kassambara A. 'Ggplot2' based publication ready plots [R package ggpubr version0.6.0]. The Comprehensive R Archive Network. Comprehensive R Archive Network(CRAN);2023.Availablefrom:https://cran.r-project.org/web/packages/ggpubr/index.html
432 433	28.	R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2013. Available from:

434 <u>http://www.R-project.org/</u>

20

435 436 437	29.	Kuhn M. Classification and regression training [R package caret version 6.0-93]. The Comprehensive R Archive Network. Comprehensive R Archive Network (CRAN); 2022. Available from: <u>https://cran.r-project.org/web/packages/caret/index.htm</u> l
438 439	30.	Tuszynski J. Package catools. CRAN. Comprehensive R Archive Network (CRAN); 2021. Available from: <u>https://cran.r-project.org/web/packages/caTools/index.html</u>
440 441 442 443	31.	He Z, Gu J, Luan T, Li H, Li C, Chen Z, et al. Comprehensive analyses of a tumor- infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA. Frontiers in Immunology. 2022;13:973974.doi:10.3389/fimmu.2022.973974
444 445 446	32.	Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: From prognosis to treatment selection. British Journal of Cancer. 2022;128(3):451–8.doi:10.1038/s41416-022-02119-4
447 448 449	33.	Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Frontiers in Immunology. 2020;11:2105.doi:10.3389/fimmu.2020.02105
450 451	34.	Wang X, Li M. Correlate tumor mutation burden with immune signatures in human cancers. BMC Immunology. 2019;20(1):4.doi:10.1186/s12865-018-0285-5
452 453 454	35.	Laumont CM, Perreault C. Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy. Cellular and Molecular Life Sciences. 2017;75(4):607–21.doi:10.1007/s00018-017-2628-4
455 456 457	36.	Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Frontiers in Immunology. 2021;12:636568.doi:10.3389/fimmu.2021.636568
458 459 460 461	37.	Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. British Journal of Cancer. 2011;105(1):93–103.doi:10.1038/bjc.2011.189
462 463 464 465	38.	Tie EN, Lai-Kwon J, Rtshiladze MA, Na L, Bozzi J, Read T, Atkinson V, Au-Yeung G, Long GV, McArthur GA, Sandhu S. Efficacy of immune checkpoint inhibitors for in-transit melanoma. Journal for immunotherapy of cancer. 2020;8(1):e000440.doi:10.1136/jitc-2019-000440
466 467 468 469 470 471 472	39.	Gorris MA, van der Woude LL, Kroeze LI, Bol K, Verrijp K, Amir AL, Meek J, Textor J, Figdor CG, de Vries IJ. Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. Journal for Immunotherapy of Cancer. 2022;10(5):e004329.doi:10.1136/jitc-2021-004329

## 473 FIGURE LEGENDS

**Figure 1:** Comparison of immune cells abundance between high and low immunogenic groups. A) Pro-tumor immune cells show no significant association

21

with lnc-IM scores. B) Association of anti-tumor immune cells with high and low lnc-IM scores.

**Figure 2:** Association of lnc-IM scores with survival predictions in TCGA-SKCM cohort (n=101). Low lnc-IM group (n=59) is associated with better survival outcomes as compared to high lnc-IM group (n=42).

**Figure 3:** Multivariate analysis to identify any confounding variables. Only immunity count (lnc-IM scores) showed significance with survival predictions (TCGA-SKCM).

**Figure 4:** Comparison of overall response rate between high TMB category and high combined antigen score among all ICI treated cohorts.

**Figure 5:** Comparing true positive rate (TPR) and false negative rate (FNR) between high TMB and high combined antigen scores. High combined antigen scoring showed improved TPR of 85% as compared to high TMB (66%). FNR also showed improvement (14%) in high combined antigen classifier.

# Pro-tumor immune cells

Lnc.IM 喜 high 喜 low

Anti-tumor immune cells





В





Hazard ratio





